Functional involvement of β3-adrenergic receptors in melanoma growth and vascularization

Journal of Molecular Medicine

Volumn 91, Issue 12, 2013, Pages 1407-1419

  Dal Monte, Massimo ^a   Casini, Giovanni ^a   Filippi, Luca ^b   Nicchia, Grazia Paola ^c   Svelto, Maria ^c   Bagnoli, Paola ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF BARI   (Italy)

Author keywords

AR pharmacology; AR silencing; Angiogenic factors; Apoptosis; B16F10 cells; Downstream effectors

Indexed keywords

1 (2 ETHYLPHENOXY) 3 (1,2,3,4 TETRAHYDRO 1 NAPHTHYLAMINO) 2 PROPANOL OXALATE; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 8; CASPASE 3; CYTOCHROME C; L 748337; NITRIC OXIDE SYNTHASE; PROPRANOLOL; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GENETIC TRANSFECTION; HYPOXIA; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR VASCULARIZATION;

ADRENERGIC BETA-3 RECEPTOR ANTAGONISTS; ANIMALS; APOPTOSIS; CELL HYPOXIA; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; MALE; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; NEOVASCULARIZATION, PATHOLOGIC; PROPANOLAMINES; RECEPTORS, ADRENERGIC, BETA-3; RNA INTERFERENCE; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84890315343     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-013-1073-6     Document Type: Article

References (41)

1. Cole SW, Sood AK (2012) Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res 18:1201-1206
2. Schuller AM (2008) Neurotransmission and cancer: implications for prevention and therapy. Anticancer Drugs 19:655-671
3. Hatiboglu MA, Kong LY, Wei J, Wang Y, McEnery KA, Fuller GN, Qiao W, Davies MA, Priebe W, Heimberger AB (2012) The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. Int J Cancer 131:8-17
4. Goundiam O, Nagel MD, Vayssade M (2010) Growth and survival signalling in B16F10 melanoma cells in 3D culture. Cell Biol Int 34:385-391
5. Sikora AG, Gelbard A, Davies MA, Sano D, Ekmekcioglu S, Kwon J, Hailemichael Y, Jayaraman P, Myers JN, Grimm EA et al (2010) Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res 16:1834-1844
6. Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M et al (2006) Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 12:939-944
7. Cao Y, Liu Q (2007) Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis. Adv Cancer Res 97:203-224
8. Ribatti D, Nico B, Perra MT, Longo V, Maxia C, Annese T, Piras F, Murtas D, Sirigu P (2010) Erythropoietin is involved in angiogenesis in human primary melanoma. Int J Exp Pathol 91:495-499
9. Nicchia GP, Stigliano C, Sparaneo A, Rossi A, Frigeri A, Svelto M (2013) Inhibition of aquaporin-1 dependent angiogenesis impairs tumour growth in a mouse model of melanoma. J Mol Med (Berl) 91:613-623
10. Saadoun S, Papadopoulos MC, Hara-Chikuma M, Verkman AS (2005) Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption. Nature 434:786-792
11. Moretti S, Massi D, Farini V, Baroni G, Parri M, Innocenti S, Cecchi R, Chiarugi P (2013) β-adrenoceptors are upregulated in human melanoma and their activation releases pro-tumorigenic cytokines and metalloproteases in melanoma cell lines. Lab Invest 93:279-290
12. De Giorgi V, Grazzini M, Gandini S, Benemei S, Lotti T, Marchionni N, Geppetti P (2011) Treatment with {beta}-blockers and reduced disease progression in patients with thick melanoma. Arch Intern Med 171:779-781
13. Lemeshow S, Sørensen HT, Phillips G, Yang EV, Antonsen S, Riis AH, Lesinski GB, Jackson R, Glaser R (2011) β-blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer Epidemiol Biomarkers Prev 20:2273-2279
14. Lamkin DM, Sloan EK, Patel AJ, Chiang BS, Pimentel MA, Ma JC, Arevalo JM, Morizono K, Cole SW (2012) Chronic stress enhances progression of acute lymphoblastic leukemia via β-adrenergic signaling. Brain Behav Immun 26:635-641
15. Perrone MG, Notarnicola M, Caruso MG, Tutino V, Scilimati A (2008) Upregulation of beta3-adrenergic receptor mRNA in human colon cancer: a preliminary study. Oncology 75:224-229
16. Chisholm KM, Chang KW, Truong MT, Kwok S, West RB, Heerema-McKenney AE (2012) β-Adrenergic receptor expression in vascular tumors. Mod Pathol 25:446-1451
17. Babol K, Przybylowska K, Lukaszek M, Pertynski T, Blasiak J (2004) An association between the Trp64Arg polymorphism in the beta3-adrenergic receptor gene and endometrial cancer and obesity. J Exp Clin Cancer Res 23:669-674
18. Huang XE, Hamajima N, Saito T, Matsuo K, Mizutani M, Iwata H, Iwase T, Miura S, Mizuno T, Tokudome S et al (2001) Possible association of beta2- and beta3-adrenergic receptor gene polymorphisms with susceptibility to breast cancer. Breast Cancer Res 3:264-269
19. Bartness TJ, Vaughan CH, Song CK (2010) Sympathetic and sensory innervation of brown adipose tissue. Int J Obes (Lond) 34(Suppl 1):S36-S42
20. Dessy C, Balligand JL (2010) Beta3-adrenergic receptors in cardiac and vascular tissues emerging concepts and therapeutic perspectives. Adv Pharmacol 59:135-163
21. Igawa Y, Michel MC (2013) Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome. N Schmied Arch Pharmacol 386:177-183
22. Matsumoto R, Otsuka A, Suzuki T, Shinbo H, Mizuno T, Kurita Y, Mugiya S, Ozono S (2013) Expression and functional role of β(3)-adrenoceptors in the human ureter. Int J Urol. doi: 10.1111/iju.12093
23. Dal Monte M, Filippi L, Bagnoli P (2013) Beta3-adrenergic receptors modulate vascular endothelial growth factor release in response to hypoxia through the nitric oxide pathway in mouse retinal explants. N Schmied Arch Pharmacol 386:269-278
24. Romana-Souza B, Otranto M, Almeida TF, Porto LC, Monte-Alto-Costa A (2011) Stress-induced epinephrine levels compromise murine dermal fibroblast activity through β-adrenoceptors. Exp Dermatol 20:413-419
25. Oikawa F, Nakahara T, Akanuma K, Ueda K, Mori A, Sakamoto K, Ishii K (2012) Protective effects of the β3-adrenoceptor agonist CL316243 against N-methyl-d-aspartate-induced retinal neurotoxicity. N Schmied Arch Pharmacol 385:1077-1081
26. Baker JG (2010) The selectivity of b-adrenoceptor agonists at human b1-, b2- and b3-adrenoceptors. Br J Pharmacol 160:1048-1061
27. Bedogni B, Powell MB (2009) Hypoxia, melanocytes and melanoma - survival and tumor development in the permissive microenvironment of the skin. Pigment Cell Melanoma Res 22:166-174
28. Frazier EP, Michel-Reher MB, van Loenen P, Sand C, Schneider T, Peters SL, Michel MC (2011) Lack of evidence that nebivolol is a β3-adrenoceptor agonist. Eur J Pharmacol 654:86-91
29. Niclauss N, Michel-Reher MB, Alewijnse AE, Michel MC (2006) Comparison of three radioligands for the labelling of human beta-adrenoceptor subtypes. N Schmied Arch Pharmacol 374:99-105
30. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN (2004) Comparative pharmacology of human beta-adrenergic receptor subtypes - characterization of stably transfected receptors in CHO cells. N Schmied Arch Pharmacol 369:151-159
31. Vrydag W, Michel MC (2007) Tools to study beta3-adrenoceptors. N Schmied Arch Pharmacol 374:385-398
32. Shan T, Ma Q, Zhang D, Guo K, Liu H, Wang F, Wu E (2011) β2-adrenoceptor blocker synergizes with gemcitabine to inhibit the proliferation of pancreatic cancer cells via apoptosis induction. Eur J Pharmacol 665:1-7
33. Barbieri A, Palma G, Rosati A, Giudice A, Falco A, Petrillo A, Petrillo M, Bimonte S, Di Benedetto M, Esposito G et al (2012) Role of endothelial nitric oxide synthase (eNOS) in chronic stress-promoted tumour growth. J Cell Mol Med 16:920-926
34. Cai HY, Xu ZJ, Tang J, Sun Y, Chen KX, Wang HY, Zhu WL (2012) The essential role for aromatic cluster in the β3 adrenergic receptor. Acta Pharmacol Sin 33:1062-1068
35. Russell ST, Hirai K, Tisdale MJ (2002) Role of beta3-adrenergic receptors in the action of a tumour lipid mobilizing factor. Br J Cancer 86:424-428
36. Dal Monte M, Martini D, Latina V, Pavan B, Filippi L, Bagnoli P (2012) Beta-adrenoreceptor agonism influences retinal responses to hypoxia in a model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 53:2181-2192
37. Ristori C, Filippi L, Dal Monte M, Martini D, Cammalleri M, Fortunato P, la Marca G, Fiorini P, Bagnoli P (2012) Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade. Invest Ophthalmol Vis Sci 52:155-170
38. Fredriksson JM, Lindquist JM, Bronnikov GE, Nedergaard J (2000) Norepinephrine induces vascular endothelial growth factor gene expression in brown adipocytes through a beta-adrenoreceptor/cAMP/protein kinase A pathway involving Src but independently of Erk1/2. J Biol Chem 275:13802-13811
39. Glasner A, Avraham R, Rosenne E, Bensih M, Zmora O, Shemer S, Meiboom H, Ben-Eliyahu S (2010) Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor. J Immunol 184:2449-2457
40. Rath G, Balligand JL, Dessy C (2012) Vasodilatory mechanisms of beta receptor blockade. Curr Hypertens Rep 14:310-317
41. Hasegawa H, Saiki I (2002) Psychosocial stress augments tumor development through beta-adrenergic activation in mice. Jpn J Cancer Res 93:729-735